cropped color_logo_with_background.png

BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM)

Study Purpose

The purpose of this study is to evaluate the effectiveness of Prostate Specific Membrane Antigen (PSMA ADC), as well as its safety and side effects for patients with advanced brain tumors. This study will also study how your body metabolizes (breaks down) PSMA ADC.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Males and females Histologically confirmed GBM (Patients with gliosarcoma are also eligible) - Assessable or measurable disease by MRI.
  • - Progression after prior treatment that includes radiation, temozolomide and bevacizumab.
-> 4 weeks since prior chemotherapy, bevacizumab and other systemic treatment and > 3 weeks from prior radiation.
  • - age >18 years.
  • - Weight < 150 kg.
  • - Karnofsky performance score > 60.
  • - Life expectancy >12 weeks.
  • - Brain MRI within 21 days prior to registration.
  • - Laboratory results requirements.
  • - Absolute neutrophil count (ANC) ≥ 1000/mm3.
  • - Platelets (Plt) ≥ 100,000/mm3.
  • - Hemoglobin (Hgb) ≥ 8.0 g/dL.
  • - Total bilirubin ≤ 2.0 mg/dL.
  • - Serum alanine transferase/ Serum aspartate transaminase (ALT/AST) ≤ 2.5x the upper limit of normal (ULN) - Serum creatinine ≤ 2.0 mg/dL.
  • - Pancreatic Amylase (p-amylase) ≤ the ULN.
  • - Negative serum pregnancy test for women of child-bearing potential.
  • - Stable corticosteroid dose at least 14 days prior to registration.
  • - Women of childbearing potential must have a negative pregnancy test.
  • - Men and women of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least 3 months thereafter.
  • - Patients must not be on enzyme-inducing anti-epileptic drugs (EIAED).
Patients may be on non-enzyme inducing anti-epileptic drugs (NEIAED) or may not be taking any anti-epileptic drugs. A list of AED that cause modest or no induction of hepatic metabolic enzymes will be discussed.

Exclusion Criteria:

  • - Non-GBM primary invasive malignant neoplasm within the five years prior to screening except for: - keratinocyte (non-melanoma) (i.e., basal cell, squamous cell) carcinoma of the skin; or low-grade papillary superficial transitional cell carcinoma of the bladder.
However, patients with stage 1 cancers not requiring cancer therapy including chemotherapy or hormone therapy, for which a lifespan of greater than 3 years without treatment is expected (such as early stage prostate cancer) may be enrolled.
  • - Clinically significant cardiac disease (New York Heart Association Class III/ IV or severe debilitating pulmonary disease.
  • - Subjects with QTc>500 msec (either Bazzett's or Fridericia's method) - Radiation therapy, cytotoxic chemotherapy, bevacizumab or other treatment for GBM within previous three weeks.
  • - Evidence of an active infection requiring ongoing intravenous antibiotic therapy.
  • - Any toxicity ≥ grade 2 (non-laboratory) (NCI CTCAE, Version 4.03) prior to first dose of study drug.
  • - Prior treatment with PSMA ADC or other therapies targeting PSMA, or other anti-body drug conjugate (ADC) products that contain monomethyl auristatin E (MMAE) (e.g., brentuximab vedotin, glembatumumab vedotin, ASG-5ME) - Known hypersensitivity reactions to PSMA ADC or any of its components.
  • - Any medical condition that in the opinion of the Investigator may interfere with a subject's participation in or compliance with the study.
- Patients with a prior history of pancreatitis

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT01856933
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 2
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Heinrich Elinzano, MD
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Heinrich Elinzano, MD
Principal Investigator Affiliation Brown University
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Other, Industry
Overall Status Completed
Countries United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

GBM, Glioblastoma Multiforme, Gliosarcoma
Additional Details

PSMA expression has been demonstrated in the tumor neovasculature of Glioblastoma Multiforme (GBM) by immunohistochemical staining. Strong reactivity to the antibody component of PSMA ADC was observed in the endothelial cells of new tumor blood vessels in GBM. Since the endothelial cells are located on the luminal surface of blood vessels, PSMA ADC does not need to cross the blood brain barrier to reach its target. Following binding and internalization of PSMA ADC, the cytotoxic component of PSMA ADC will be released and destroy the neovasculature that supports tumor growth. Therefore, PSMA ADC may be an active treatment for GBM. Bevacizumab, an inhibitor of angiogenesis, has been shown to be effective in improving progression-free survival as a single agent. Thus PSMA ADC, which targets tumor angiogenesis by a mechanism different from that of bevacizumab, may be a novel therapeutic modality for GBM. A phase 2 study of PSMA ADC is proposed for patients with GBM that have progressed after standard treatment that includes radiation, temozolomide and bevacizumab. A phase 1 study of PSMA ADC in prostate cancer is ongoing and a phase 2 dose level of 2.5 mg/kg IV every 3 weeks has been defined. Treatment after bevacizumab failure for patients with GBM is a major unmet medical need. If activity were demonstrated in this trial, a definitive randomized study would be proposed.

Arms & Interventions

Arms

Experimental: PSMA ADC

2.5 mg/kg, IV, over 60 minutes every 3 weeks

Interventions

Drug: - PSMA ADC

2.5 mg/kg, IV, over 60 minutes every 3 weeks

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

Rhode Island Hospital, Providence, Rhode Island

Status

Address

Rhode Island Hospital

Providence, Rhode Island, 02903

UT Southwestern, Dallas, Texas

Status

Address

UT Southwestern

Dallas, Texas, 75235